175 related articles for article (PubMed ID: 26643932)
1. Pertussis specific cell-mediated immune responses ten years after acellular pertussis booster vaccination in young adults.
Gröndahl-Yli-Hannuksela K; Kauko L; Van Der Meeren O; Mertsola J; He Q
Vaccine; 2016 Jan; 34(3):341-9. PubMed ID: 26643932
[TBL] [Abstract][Full Text] [Related]
2. Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens.
Scheifele DW; Ochnio JJ; Halperin SA
Pediatr Infect Dis J; 2009 Nov; 28(11):985-9. PubMed ID: 19755930
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of IL-10 gene promoter region: association with T cell proliferative responses after acellular pertussis vaccination in adults.
Gröndahl-Yli-Hannuksela K; Vahlberg T; Ilonen J; Mertsola J; He Q
Immunogenetics; 2016 Oct; 68(9):733-41. PubMed ID: 27282930
[TBL] [Abstract][Full Text] [Related]
4. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
5. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
[TBL] [Abstract][Full Text] [Related]
6. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine.
Edelman KJ; He Q; Makinen JP; Haanpera MS; Tran Minh NN; Schuerman L; Wolter J; Mertsola JA
Clin Infect Dis; 2004 Jul; 39(2):179-85. PubMed ID: 15307026
[TBL] [Abstract][Full Text] [Related]
7. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
[TBL] [Abstract][Full Text] [Related]
8. Immune responses to pertussis antigens in infants and toddlers after immunization with multicomponent acellular pertussis vaccine.
Fadugba OO; Wang L; Chen Q; Halasa NB
Clin Vaccine Immunol; 2014 Dec; 21(12):1613-9. PubMed ID: 25253666
[TBL] [Abstract][Full Text] [Related]
9. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
[TBL] [Abstract][Full Text] [Related]
10. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immunity after pertussis vaccination and after natural infection.
Zepp F; Knuf M; Habermehl P; Schmitt HJ; Meyer C; Clemens R; Slaoui M
Dev Biol Stand; 1997; 89():307-14. PubMed ID: 9272364
[TBL] [Abstract][Full Text] [Related]
12. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection.
Barkoff AM; Gröndahl-Yli-Hannuksela K; Vuononvirta J; Mertsola J; Kallonen T; He Q
Vaccine; 2012 Nov; 30(48):6897-902. PubMed ID: 22981763
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
Chan SH; Tan PT; Han HH; Bock HL
Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
[TBL] [Abstract][Full Text] [Related]
14. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
[TBL] [Abstract][Full Text] [Related]
15. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
Mertsola J; Van Der Meeren O; He Q; Linko-Parvinen A; Ramakrishnan G; Mannermaa L; Soila M; Pulkkinen M; Jacquet JM
Clin Infect Dis; 2010 Sep; 51(6):656-62. PubMed ID: 20704493
[TBL] [Abstract][Full Text] [Related]
16. Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium.
Vandermeulen C; Theeten H; Rathi N; Kuriyakose S; Han HH; Sokal E; Hoppenbrouwers K; Van Damme P
Vaccine; 2015 Jun; 33(26):3026-34. PubMed ID: 25613716
[TBL] [Abstract][Full Text] [Related]
17. Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and nonpregnant women.
Huygen K; Caboré RN; Maertens K; Van Damme P; Leuridan E
Vaccine; 2015 Aug; 33(33):4117-23. PubMed ID: 26187257
[TBL] [Abstract][Full Text] [Related]
18. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
[TBL] [Abstract][Full Text] [Related]
19. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults.
Scott LJ
BioDrugs; 2010 Dec; 24(6):387-406. PubMed ID: 21043546
[TBL] [Abstract][Full Text] [Related]
20. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination.
Rieber N; Graf A; Belohradsky BH; Hartl D; Urschel S; Riffelmann M; Wirsing von König CH; Liese J
Vaccine; 2008 Dec; 26(52):6929-35. PubMed ID: 18852002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
